rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    ARCT
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Arcturus Therapeutics Announces $50 Million Investment by Meiji Seika Pharma as Part of Expanded Collaboration
      Nov 16Yahoo FinanceARCT
      Arcturus at Guggenheim healthcare conference: 2027 data looms
      Nov 9Investing.comARCT
      Arcturus: 'Hold' Next-Gen ARCT-2601 OTC Candidate And Continued CF Advancement

      Arcturus Therapeutics remains a Hold as key mRNA pipeline data nears. Click here to read my most recent analysis of Arcturus stock.

      Nov 9Seeking AlphaARCT
      What Arcturus Therapeutics (ARCT) Said on Its Q3 Earnings Call
      Nov 6Yahoo FinanceARCT
      Arcturus Therapeutics Q3 2026 Earnings Call Transcript
      Nov 5BenzingaARCT
      Arcturus Therapeutics (ARCT) Reports Q3 Loss, Beats Revenue Estimates
      Nov 5Yahoo FinanceARCT
      Arcturus Therapeutics Announces Third Quarter 2026 Financial Results and Pipeline Progress
      Nov 5Yahoo FinanceARCT
      Earnings To Watch: Arcturus Therapeutics Holdings Inc (ARCT) Q3 2026 -- GF Value Sees 59% Downside
      Nov 4Yahoo FinanceARCT
      Arcturus Therapeutics to Report Third Quarter Financial Results and Provide Corporate Update on November 5, 2026
      Oct 26Yahoo FinanceARCT
      Transcript: Arcturus Therapeutics Q2 2026 Earnings Conference Call - Arcturus Therapeutics (NASDAQ:ARCT)

      Arcturus Therapeutics (NASDAQ:ARCT) released second-quarter financial results and hosted an earnings call on Thursday. Read the complete transcript below. This content is powered by Benzinga APIs. For comprehensive

      Oct 14BenzingaARCT
      Arcturus Therapeutics (ARCT) Receives a Buy from Leerink Partners

      Detailed price information for Arcturus Therapeutics Ltd (ARCT-Q) from The Globe and Mail including charting and trades.

      Oct 10The Globe and MailARCT
      Wells Fargo Keeps Their Buy Rating on Arcturus Therapeutics (ARCT)

      Detailed price information for Arcturus Therapeutics Ltd (ARCT-Q) from The Globe and Mail including charting and trades.

      Oct 6The Globe and MailARCT
      4 RNA Therapeutics Stocks Leading the Next Wave of Innovation
      Sep 28Yahoo FinanceALNYARCT
      Analysts Are Bullish on Top Healthcare Stocks: Arcturus Therapeutics (ARCT), ACADIA Pharmaceuticals (ACAD)

      Detailed price information for Acadia Pharmaceutica (ACAD-Q) from The Globe and Mail including charting and trades.

      Sep 25The Globe and MailARCT
      Arcturus Highlights ARCT-810 Phase II Data, Unveils Next-Gen OTC Therapy Platform
      Sep 25Yahoo FinanceARCT
      Exclusive BAC Article: Arcturus Therapeutics; OTC Deficiency Change FDA Allowed ARCT-2601 YE 2026, Ph 3 Decision ARCT-032 CF Q4 2026, And Catalysts (NASDAQ:ARCT)
      Sep 24Seeking AlphaARCT
      Arcturus Therapeutics Shares Rise After OTC Deficiency Data, Citigroup Upgrade

      Arcturus Therapeutics (ARCT) shares rose 6.3% in Thursday afternoon trading, a day after it reported

      Sep 24Yahoo FinanceARCT
      Why Is Arcturus Therapeutics Stock Gaining Thursday? - Arcturus Therapeutics (NASDAQ:ARCT)

      Arcturus Therapeutics (ARCT) surged over 6% after sharing positive Phase 2 interim data for its OTC deficiency drug, ARCT-810.

      Sep 24BenzingaARCT
      Arcturus Gets Citi Upgrade After Positive Liver Disease Study Data – But BTIG Says Therapy’s Benefit Is Hard To Measure

      Citi upgraded Arcturus to ‘Buy’ and raised the price target to $20 from $8, according to The Fly.

      Sep 24Yahoo FinanceARCT
      Arcturus stock upgraded to Buy at Citi (ARCT:NASDAQ)
      Sep 24Seeking AlphaARCT
      Citigroup Upgrades Arcturus Therapeutics to Buy From Neutral, Adjusts PT to $20 From $8
      Sep 24Yahoo FinanceARCT
      Arcturus Therapeutics Holdings Inc. (ARCT) Discusses Phase II Data for OTC Deficiency and Advances in mRNA Liver Therapeutics Platform - Slideshow (NASDAQ:ARCT) 2026-09-24
      Sep 24Seeking AlphaARCT
      Arcturus sees positive results from mid-stage trial of RCT-810 in OTC deficiency

      Arcturus (ARCT) reports phase 2 ARCT-810 results lowering ammonia in OTC deficiency and plans ARCT-2601 dosing with FDA input. Read more here.

      Sep 23Seeking AlphaARCT
      Arcturus Therapeutics Announces Interim OTC Deficiency Phase 2 Results and Introduces LUNAR 2.0™ Next-Generation mRNA Delivery Platform

      SAN DIEGO, September 23, 2026--Arcturus Therapeutics Holdings Inc. (the "Company," "Arcturus," Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory therapeutics, today announced encouraging interim Phase 2 results from ARCT-810 in ornithine transcarbamylase (OTC) deficiency and introduced LUNAR 2.0™, the Company’s next-generation mRNA delivery platform, and additional liver pipeline programs.

      Sep 23Yahoo FinanceARCT
      Arcturus stock ticks up on Phase 2 data, new mRNA platform
      Sep 23Investing.comARCT
      Arcturus Therapeutics: A Speculative Buy For Their OTC Deficiency Program (NASDAQ:ARCT)
      Sep 21Seeking AlphaARCT
      Arcturus Therapeutics to Present Ornithine Transcarbamylase (OTC) Deficiency Phase 2 Clinical Data and Provide Update on mRNA Liver Therapeutics Platform
      Sep 18Yahoo FinanceARCT
      Citi Keeps Their Hold Rating on Arcturus Therapeutics (ARCT)

      Detailed price information for Arcturus Therapeutics Ltd (ARCT-Q) from The Globe and Mail including charting and trades.

      Sep 11The Globe and MailARCT
      Arcturus Therapeutics at cantoral global healthcare conference: data catalysts ahead
      Sep 10Investing.comARCT
      Arcturus Therapeutics at Citi summit: two catalysts, one pivotal year
      Sep 9Investing.comARCT
      Why is Arcturus Therapeutics stock surging today?
      Sep 1Investing.comARCT
      Arcturus Therapeutics to Participate in Upcoming Investor Conferences

      SAN DIEGO, August 31, 2026--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today announced that the Company will participate in the following investor conferences:

      Aug 31Yahoo FinanceARCT
      Arcturus, Moderna down on BioNTech trial setback (ARCT:NASDAQ)
      Aug 28Seeking AlphaARCTBNTXMRNA
      Arcturus Therapeutics (ARCT) Just Flashed Golden Cross Signal: Do You Buy?

      Is it a good or bad thing when a stock experiences a golden cross technical event?

      Aug 27Yahoo FinanceARCT
      mRNA Therapeutics Market Outlook Report 2026-2035 Featuring Profiles of Arcturus Therapeutics, BioNTech, CureVac, Moderna, Providence Therapeutics, RNAimmune, Recode Therapeutics, and More

      Expanding oncology and rare disease pipelines, strategic partnerships, and advances in delivery technologies are expected to drive significant market growthDublin, Aug. 26, 2026 (GLOBE NEWSWIRE) -- The "mRNA Therapeutics Market by Target Indication (Non-Small Cell Lung Cancer, Melanoma, Muscle-Invasive Urothelial Carcinoma, Propionic Acidemia, and Cystic Fibrosis) and Geographical Regions (North America, Europe, and Asia-Pacific) - Trends and Forecast, Till 2035" has been added to ResearchAndMar

      Aug 26Yahoo FinanceARCT
      12 Health Care Stocks Moving In Friday's Intraday Session
      Aug 21BenzingaARCTHOWLJUNSLSTA

      This is the newest page. Registered accounts read further back.